Khorana risk score
Estimate risk of chemotherapy-associated thrombosis
This risk model for chemotherapy-associated thrombosis was developed and validated using an observational cohort of cancer patients initiating chemotherapy within the United States. Inclusion criteria were patients starting a new chemotherapy regimen, and those who were expected to complete at least 4 cycles. Only venous thromboembolism events were included, and were diagnosed by the treating clinician.
Using baseline clinical and biochemical characteristics in patients starting chemotherapy, a risk score for chemotherapy-associated VTE events classifies patients into low, intermediate, and high risk groups.
Previous thromboprophylaxis trials in cancer patients receiving chemotherapy have not demonstrated a significant benefit. Identifying cancer patients at high risk of VTE may help guide clinican decision-making. Prospective trials evaluating the clinical applicability of this score, and its role in patient selection for thromboprophylaxis have not yet been conducted.
- [1]Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW.: Development and validation of a predictive model for chemotherapy-associated thrombosis.Blood 2008 May 15, 111 (10): 4902-7
Results
Real-time automated computation
This risk model for chemotherapy-associated thrombosis was developed and validated using an observational cohort of cancer patients initiating chemotherapy within the United States. Inclusion criteria were patients starting a new chemotherapy regimen, and those who were expected to complete at least 4 cycles. Only venous thromboembolism events were included, and were diagnosed by the treating clinician.
Using baseline clinical and biochemical characteristics in patients starting chemotherapy, a risk score for chemotherapy-associated VTE events classifies patients into low, intermediate, and high risk groups.
Previous thromboprophylaxis trials in cancer patients receiving chemotherapy have not demonstrated a significant benefit. Identifying cancer patients at high risk of VTE may help guide clinican decision-making. Prospective trials evaluating the clinical applicability of this score, and its role in patient selection for thromboprophylaxis have not yet been conducted.
- [1]Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW.: Development and validation of a predictive model for chemotherapy-associated thrombosis.Blood 2008 May 15, 111 (10): 4902-7